FAQ on Lantern Pharma's EU Patent for AI-Designed Cancer Drug LP-284

What is LP-284 and what does it treat?

LP-284 is a clinical-stage drug candidate developed by Lantern Pharma for the treatment of relapsed or refractory non-Hodgkin’s lymphoma, with Orphan Drug Designations for MCL and HGBL.

How was LP-284 developed?

LP-284 was developed using Lantern Pharma’s RADR(R) AI platform, which leverages over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms.

What does the EU patent for LP-284 cover?

The EU patent covers a composition of matter for LP-284, granting exclusivity through 2039 and supporting global commercialization efforts alongside existing IP in the U.S. and Japan.

What is the significance of the EU patent for Lantern Pharma?

The EU patent enhances Lantern Pharma’s intellectual property portfolio, bolsters its strategic partnership potential, and supports the global commercialization of LP-284.

What is the market potential for LP-284?

LP-284 targets a $4 billion global market, with its rapid development timeline and cost efficiency making it a promising candidate for treating specific cancers.

What is Lantern Pharma’s RADR(R) AI platform?

RADR(R) is Lantern Pharma’s proprietary AI and machine learning platform that accelerates oncology drug discovery and development by analyzing vast amounts of oncology-focused data.

How long does it take for Lantern Pharma to advance a drug program from AI insights to clinical trials?

On average, Lantern Pharma advances its newly developed drug programs from initial AI insights to first-in-human clinical trials in 2-3 years.

What are the cost efficiencies of Lantern Pharma’s drug development process?

Lantern Pharma’s drug development process costs approximately $2.5 million per program, significantly lower than traditional methods due to its AI-driven approach.

Where can I find more information about Lantern Pharma and LP-284?

More information is available in Lantern Pharma’s newsroom at https://ibn.fm/LTRN and the full press release can be viewed at https://ibn.fm/Rx6Jq.

Who can I contact for more information about BioMedWire?

For more information about BioMedWire, visit https://www.biomedwire.com or contact [email protected].